Appendix 3: Angus HSCP Prescribing Management Plan: Active Interventions 2018/19

Initiative	Rationale	Actions	Lead	Status (RAG)
	Being dy	vnamic to change		
Practice review report	Provision of key information to practices to enable discussion and identify areas to address	Plans to be issued to all practices by June 2018	SJ	
		Practice priorities for action in 2018/19 to be submitted to HSCP by 30 June 2018	MLR	
		Audits and claims for all actions completed to be submitted by 31 st January 2019	RG	
		Audits to be used to inform 2019/20 priorities	SJ	
		GP Prescribing/Pharmacist Led initiatives – see subsection	SJ	
Maintaining momentum	To maintain profile and momentum around prescribing position in relation to prescribing	Prescribing as a standing item with a written report at each Clinical Partnership Group meeting.	MLR	
		Continued review of top 50 GIC every quarter to monitor and adapt ongoing plans.	SJ	
		Annual PLT programme on prescribing topics to support high quality prescribing and realistic medicine	RG/SJ	
Monitoring of formulary compliance	Formulary choices are based upon cost effectiveness and clinical best practice	Quarterly review of data by practice, cluster and Angus wide, with inclusion within Clinical Partnership Group reporting where required.	MLR/BM	
Establishment of Prescribing of Non- Medicines Advisory Group	To ensure cost effective use of prescribed non-medicines	A regional group co-chaired by Angus' Prescribing Clinical Lead, will identify further areas of improvement for Non- medicines prescribing within 2018/19	LS	
Technical prescribing efficiencies	Ensure opportunities are identified to maximise technical efficiencies/switches	Regionally coordinated and locally implemented switches are expedited where clinically safe and approved by local prescribing leads	SJ/MLR/MB	
Horizon scanning	Ensure early identification in event of pricing changes and/or local deterioration in prescribing position	Clinical lead and Prescribing Support Unit monitoring and actioning on a weekly basis.	SJ/MB	
		est use of resources		
Pharmacotherapy service development	A requirement of the 2018 GMS contract this will create capacity and the potential to support consistency in prescribing and management of prescribing processes pan Angus.	Implementation of the pharmacotherapy actions as outlined in the Primary Care Improvement Plan.	MLR/AC/RG	
Improved prescribing of psychotropics through improved mental health pathways	Key priority for 2018/19 regionally recognising impact of mental health prescribing on variation and spend- with risk in some cases of harm	Angus will support the ongoing use of psychotropic medications and making best use of non-drug options.	RB/AC/SJ	

Diabetes Pathway Reviews	Key regional priority for	Angus will support the development,	CS/AC/SJ	
	2018/19 recognising	testing and implementation of new		
	variation in spend and	regional pathways with an increased		
	potential harm	emphasis on supporting lifestyle		
	P	changes and a more personalised		
		approach to diabetes management.		
	Quality Improvem	ent of Practice Prescribing	I	
Medicines of low clinical	Support cost effective and	Angus will support the planning	SJ	
value	efficient prescribing	process regionally and ensure		
		implementation of recommendations		
		locally.		
P-DQIP	Improved use of P-DQIP will	Ongoing roll-out of P-DQIP to	MLR	
	can improve the safety pf	practices. Integration of this tool		
	prescribing	within Pharmacist polypharmacy		
		reviews		
	Supporting Eff	ective Communications		
Improve both internal and	To ensure accurate and	Ongoing updates of ScriptSwitch to	SJ	
external communication of	consistent communication re	reflect current prescribing plans		
prescribing changes	current status to all	Primary Care Prescriber bulletin	SJ	
	prescribers and public	developed monthly by Prescribing		
	members in Angus	Lead and circulated to all prescribers		
		Monthly update to CPG on prescribing	MLR/SJ	
		status		
		All technical switches discussed within	MLR/MB	
		practices with practice lead prior to		
		initiation		
		Series of public communications plan	RG/AC	
		which are complimentary to NHS		
		Tayside wide communication plans		

GP Prescribing Initiatives			
Polypharmacy	Harm associated with polypharmacy is well evidenced.	Practices encouraged to consider GP led Level 3 polypharmacy reviews for all high-risk patients as outlined in project plans provided for 2018/19.	
Nitrofurantoin	Variation in practice pan Angus. Risks associated with long term use.	Practices encouraged to consider reviewing all patients on repeat prescriptions.	
Lidocaine	Despite significant reduction in spend, prescribing rates in Angus remain above national average. Limited evidence base for effectiveness has resulted in discontinuation of support for prescribing.	Practices encouraged to consider reviewing all patients on repeat prescriptions, with support provided for non-pharmacological interventions.	
Solifenacin	Reduce anticholinergic burden in patients High reduction in rates of prescribing in practices who have completed reviews	Practices who have not yet completed reviews encouraged to consider reviewing all patients on repeat prescriptions. Supporting materials provided.	
Trazodone	Amber in Tayside Area Formulary. Significant variation in prescribing.	Practices encouraged to review any patients not recently reviewed. Alternatives suggested where prescribing cannot be stopped.	
Edoxaban	Edoxaban approved as first line DOAC for NVAF. High	Practices encouraged to continue to review patients and consider for switching DOAC to	

		l	
	switch rates achieved-	Edoxaban.	
	stretch target applied to	Deadline for submission of claims extended to	
	maximise gain	July 2018	
Pharmacist-Led Initiatives			
High value, non-formulary	Identify scale and	In June-July a scoping exercise of all high value -	
prescribing monitoring	governance processes	non-formulary prescribing will be completed by	
	related to this area of	pharmacy teams, the results of which will be	
	prescribing	considered at Angus PMG for further action	
Regional implementation plans			
Oral nutritional support	Supported review of all	Roll out in South East Angus	
	patients on ONS to ensure a	Roll out in South West Angus	
	'food first' approach and	Roll out in North West Angus	
	management in line with	Roll out in North East Angus	
	revised ONS formulary		
Stoma Accessories	Supported review of all	Test process in one Angus practice	
	patients to ensure	Complete Angus roll out	
	management in line with	Extend to include stoma bags in 2018/19	
	revised formulary		
Emollients	Improve use of cost	Clinical lead monitoring price changes and	
	effective emollients. Sustain	ensuring Scriptswitch guidance accurate	
	and further improve on	Improved links with Primary and Secondary care	
	significant savings already	choices including Formulary revision	
	delivered	Reinforcement of key messages & highlighting	
		variance via Clinical Partnership Group and	
		Primary Care Prescriber	
		Practices with high levels of spend encouraged in	
		practice reports to address.	
Liothyronine	High spend – largely	Proposed review of all patients on liothyronine	
	secondary care initiated.	by specialist services with view to switching.	
	Limited evidence base for		
	effectiveness with		
	discontinuation of support		
	for prescribing.		
Wound and catheter care	Potential reduction in costs	Service manager in Angus tasked with scoping,	
	and wastage associated	implementing and maximising roll out of regional	
	with moving from	programme in Angus.	
	prescribing wound/catheter		
	care to accessing via stock		
	order		

Lead abbreviations

- AC Dr Alison Clement, Clinical Director Angus HSCP
- SJ Dr Scott Jamieson, Prescribing Lead Angus HSCP
- MLR Michelle Logan-Rena, Pharmacy Lead Angus HSCP
- RG Primary Care Manager, Angus HSCP
- BM Brian McGregor, Pharmacy Data Analyst, PSU NHS Tayside
- RB Dr Roger Blake, Lead Clinician for General Adult Psychiatry
- CS Dr Chris Schofield, Consultant Endocrinologist
- MB Mark Batey, Prescribing Support Technician, NHS Tayside